CSIMarket Company Name, Ticker, Suppliers, else..
 
Cyclo Therapeutics Inc   (NASDAQ: CYTH)
 
Price: $0.7206 $0.01 1.393%
Day's High: $0.73 Week Perf: 7.63 %
Day's Low: $ 0.63 30 Day Perf: -10.14 %
Volume (M): 188,200 52 Wk High: $ 0.00
Volume (M$): $ 136 52 Wk Avg: $0.00
Open: $0.66 52 Wk Low: $0.00



 Market Capitalization (Millions $) 21
 Shares Outstanding (Millions) 29
 Employees 29
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Cyclo Therapeutics Inc is a biotechnology company that focuses on developing innovative therapies for rare diseases. The company utilizes a proprietary drug delivery technology called Trappsol Cyclo to develop treatments for various diseases that currently have limited or no treatment options. Cyclo Therapeutics is primarily focused on developing therapies for diseases that affect the central nervous system, including diseases such as Niemann-Pick Disease Type C (NPC), Alzheimer's disease, and stroke. The company's goal is to improve the lives of patients with rare diseases by providing effective and safe therapies that can potentially slow down or halt the progression of these diseases.


   Company Address: 6714 NW 16th Street, Suite B Gainesville 32653 FL
   Company Phone Number: 418-8060   Stock Exchange / Ticker: NASDAQ CYTH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BLUE      % 
EDIT   -3.14%    
FDMT   -3.98%    
PLX        4.44% 
RGNX        2.35% 
SGMO      0% 
• View Complete Report
   



Business Update

Tiny Miracles Cyclo Therapeutics Charts a New Path in NPC1 Treatment for the Youngest Patients,

Published Sat, Feb 8 2025 4:15 PM UTC

Unraveling Hope in Tiny Hearts: Cyclo Therapeutics Unveils Promising Phase 3 Data for NPC1 Treatment In a heartfelt juncture of science and compassion, Cyclo Therapeutics, Inc. (Nasdaq: CYTH) continues to blaze a trail in the field of rare disease treatment, with the most recent revelation from its TransportNPC Phase 3 open-label sub-study. Revealed at the prestigious 21st A...
Business Update

Cyclo Therapeutics A New Dawn in the Treatment of Niemann-Pick Disease Type C1,

Published Thu, Sep 5 2024 2:09 PM UTC

Groundbreaking Progress in Niemann-Pick Disease Type C1 Treatment: Cyclo Therapeutics Reports Promising Data from Phase 3 Study In an age where biomedical innovation is key to developing effective treatments for rare and complex diseases, Cyclo Therapeutics, Inc. (Nasdaq: CYTH) has emerged as a significant player. The company recently announced encouraging preliminary safety...
Business Update

Rafael Holdings and Cyclo Therapeutics Merge to Propel Rare Disease Treatments Amid European Patent Win an...

Published Thu, Aug 22 2024 1:37 PM UTC

CSIMarket.com News In a significant move that aims to make transformative strides in biotechnology, Rafael Holdings, Inc. (NYSE: RFL) and Cyclo Therapeutics, Inc. (Nasdaq: CYTH) have announced a definitive merger agreement. This strategic alliance aims to synergize their efforts, capitalizing on Cyclo Therapeutics pioneering work on Trappsol Cyclo, a promising treatment f...
Business Update

Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Published Thu, Aug 15 2024 1:47 PM UTC

Cyclo Therapeutics: A Transformative Second Quarter Amid Pivotal Milestones and Financial DevelopmentsGainesville, Fla. Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical-stage biotechnology company committed to developing life-changing medicines through science and innovation, announced its financial results for the second quarter of 2024, alongside providing a comprehe...
Business Update

Cyclo Therapeutics Achieves European Patent Approval for Innovative Alzheimers Treatment, Signaling a New Era in N...

Published Mon, Jul 29 2024 2:21 PM UTC

Gainesville, Fla. Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical-stage biotechnology firm committed to developing transformative medicines through cutting-edge scientific research, today announced a significant milestone in its quest to address neurodegenerative diseases. The European Patent Office has issued a notice of decision to grant the company s European patent...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 23.78
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.05
Working Capital Ratio 0.17
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.02 $
Revenues (TTM) 0.03 $
Cash Flow (TTM) -
Cash 0.03 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 30,025
Net Income per Employee (TTM) -648,921
Receivable Turnover Ratio (TTM) 7.49
Inventory Turnover Ratio (TTM) 0.52
Asset Turnover Ratio (TTM) 0.12

Profitability Ratios Current
Gross Margin (MRQ) 92.81 %
Operating Margin (MRQ) -3545.95 %
Net Margin (MRQ) -3778.44 %
Net Cash Flow Margin (MRQ) -82.9 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.